@TJMeehan1 Tim M

Tim M posts on X about $nvax, sanofi, ceo, scott the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

[--] Week [-----] +875%
[--] Month [-----] +335%

Mentions: [--] #

Followers: [---] #

[--] Week [---] +11%
[--] Month [---] +21%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 31% finance 19% technology brands 4% social networks 3% exchanges 1% countries 1% cryptocurrencies 1%

Social topic influence $nvax #14, sanofi #29, ceo 9%, scott 7%, market #2201, strong 4%, thomson reuters 4%, level 3%, twitter 3%, bank 3%

Top accounts mentioned or mentioned by @doneford @novavax @wsj @danielepark @johncjacobs @rwmalonemd @tat001122tat @jikkyleaks @tat0001122tat @kevinmckernan @leahlibresco @gzuckerman @trvsrdrgz2 @thechiefnerd @thomasbanacek @lewhyte @modernatx @matthewherper @2025bill @truthinnumber

Top assets mentioned Novavax Inc (NVAX) Sanofi (SNY) Thomson Reuters Corporation (TRI) Dana Incorporated (DAN) GSK plc (GSK) GameStop, Corp. (GME)

Top Social Posts

Top posts by engagements in the last [--] hours

"@TheChiefNerd Guess who was on Pfizers BOD when this allegedly happened. Shocking Pfizer Compliance Whistleblower Says Certain CANADIAN Government Officials Were Paid [--] Million $$$ By Pfizer During "Covid." A Freedom Of Information Request MUST Be Done To Find Out Names Was It The Loudest Ones Telling Us To Roll Up Our Sleeves https://t.co/LwxhUnQumy Shocking Pfizer Compliance Whistleblower Says Certain CANADIAN Government Officials Were Paid [--] Million $$$ By Pfizer During "Covid." A Freedom Of Information Request MUST Be Done To Find Out Names Was It The Loudest Ones Telling Us To Roll Up"
X Link 2026-02-11T21:22Z [--] followers, [--] engagements

"While the RTF decision has sparked debate lets clarify on HD flu vaccines & hospitalization risk. Claiming no reduction overlooks key evidence: Multiple RCTs/meta-analyses show HD (e.g. Fluzone HD) reduces flu-related hospitalizations by 20-32% vs SD in adults 65+: NEJM [----] (GALFLU trial): 31.8% rVE against flu hosp. Lancet [----] pooled analysis (FLUNITY-HD): 31.9% rVE vs SD for flu hosp; 8.8% for pneumonia/flu. J Infect [----] meta-analysis: 23.5% rVE for P&I hosp 7.3% all-cause. Some trials (e.g. INVESTED [----] in HF patients) found no sig diff and benefits vary by season/endpoint (e.g."
X Link 2026-02-12T22:55Z [---] followers, [---] engagements

"Politics buried Novavaxs COVID vaccine despite its solid data and better safety profile. FDA/NIH pushed mRNA hard instead sidelining the protein-based option many wouldve preferred. Moderna probably figured the same favoritism would carry over to their flu trial so they picked the easier comparator (regular Fluarix) over the high-dose benchmark. It backfired gave FDA reason to push back and now EBV (mRNA-1189) HSV shingles programs are getting cut or slowed. Fear not on EBV thoughprogress is rolling without the mRNA drama. NIHs gp350-Ferritin nanoparticle vaccine (adjuvanted with Novavaxs"
X Link 2026-02-13T20:56Z [---] followers, [---] engagements

"@Thomas_Banacek Actually FDAs [----] guidance on flu vaccine licensure emphasizes adequate and well-controlled trials (21 CFR 601.25) and ACIP has preferentially recommended high-dose/adjuvanted shots for 65+ since [----] based on superior efficacy data. Modernas standard-dose comparator didnt meet that barprior admins waived it but enforcing standards isnt making up excuses. Its ensuring real benefits for seniors. Novavaxs adjuvanted combos are thriving under fair review. https://twitter.com/i/web/status/2022785331980890571 https://twitter.com/i/web/status/2022785331980890571"
X Link 2026-02-14T21:29Z [---] followers, [--] engagements

"Grok: Why $GSK should consider licensing $NVAXs Matrix-M adjuvant to upgrade Shingrix: Market Opportunity Shingles vaccine market $5.5B in [----] (from $4.8B in 2024) potentially $811B+ by [--------] (CAGR 915%). Dementia risk reduction studies could supercharge demand and expand labels. $GSKs Position & Weak Spot $GSKs Shingrix holds 80% share $44.5B annual sales. Strong efficacy but AS01 side effects drive 2030% second-dose dropout. $NVAX Matrix-M Edge Proven better tolerability (seen in $NVAX COVID trials) could lift completion rates 1020% and reduce antigen needs lower COGS higher margins."
X Link 2026-01-28T20:19Z [---] followers, [---] engagements

"we cant pin this solely on the FDA. Moderna took a calculated risk by sticking with a standard-dose comparator like GSKs Fluarix (which holds 25% US market share) instead of a high-dose option like Sanofis Fluzone HD (with 40-50% share and higher antigen levels for better efficacy in seniors). Why opt for a lesser benchmark that doesnt match the best-available standard per ACIP guidelines Every trial carries inherent risksModerna gambled on prior FDA feedback holding up but perhaps they amplified that risk by choosing a comparator that made superiority easier to show but invited scrutiny."
X Link 2026-02-13T00:17Z [---] followers, [--] engagements

"@l_e_whyte Great reporting on the internal FDA tensionsPrasads overruling of career staff on Modernas mRNA-1010 RTF does seem part of a broader pattern of U-turns as seen in cases like ImmunityBios ANKTIVA sBLA (May [----] contradicted prior guidance on single-arm data) and Savaras MOLBREEVI BLA (also May [----] additional CMC requests despite no safety flags). The personnel complaints (harassment retaliation berating) and $65k taxpayer-funded commutes add to the scrutiny on his leadership as a known Covid-vax critic. That said Moderna isnt blamelessthey took a gamble using GSKs Fluarix"
X Link 2026-02-13T00:22Z [---] followers, [---] engagements

"Prasads overruling of career staff on Modernas mRNA-1010 RTF does seem part of a broader pattern of U-turns as seen in cases like ImmunityBios ANKTIVA sBLA (May [----] contradicted prior guidance on single-arm data) and Savaras MOLBREEVI BLA (also May [----] additional CMC requests despite no safety flags). The personnel complaints (harassment retaliation berating) and $65k taxpayer-funded commutes add to the scrutiny on his leadership as a known Covid-vax critic. That said Moderna isnt blamelessthey took a gamble using GSKs Fluarix (standard-dose 25% US market share) as the primary comparator"
X Link 2026-02-13T00:28Z [---] followers, [--] engagements

"@LeahLibresco The core issue here is Modernas own choice in trial designthey knowingly used a standard-dose comparator like GSKs Fluarix Quadrivalent (with roughly 20-25% US market share in recent seasons) instead of aligning with the best-available standard of care for older adults such as Sanofis high-dose Fluzone HD (which dominates with 40-50% share and superior efficacy in seniors per ACIP/CDC guidance). Why take that risk when high-dose options set the tougher but more defensible benchmark It made showing superiority statistically easier against a lower-bar control but it backfired when"
X Link 2026-02-13T00:53Z [---] followers, [---] engagements

"Moderna took a calculated risk in their pivotal Phase [--] trial by using GSKs standard-dose Fluarix as the main comparatordespite the FDAs earlier recommendation to use a high-dose option like Sanofis Fluzone HD (which holds a much larger 40-50% share in seniors and offers higher antigen content for better efficacy in that group per ACIP guidelines). Sticking with a lesser benchmark made it easier to demonstrate superiority (as seen in the 27% relative efficacy win) but it also opened the door to later FDA criticism that the trial didnt reflect the best-available standard of care for older"
X Link 2026-02-13T02:23Z [---] followers, [---] engagements

"@2025_bill The high-dose vaccine is not approved for those under [--] and the RTF does not focus on that age group. The P303 Part C study in adults [--] compared mRNA-1010 to high-dose (Fluzone HD) and demonstrated superior immunogenicity with higher antibody titers and seroconversion rates against all strains. Immunogenicity serves as a surrogate endpoint. FDA requires primary efficacy data such as rVE against confirmed ILI outpatient visits or hospitalizations from a large trial using the best-available comparator for seniors. P303 Part C emphasized safety and immunogenicity not powered for"
X Link 2026-02-14T01:42Z [---] followers, [--] engagements

"Moderna has always known they couldnt compete on a level playing field. If they believed they could compete1) they would have used the proper comparator2) theyd run another trial. The market is huge. The tell is that they cry foul and quit. Pfizer and Sanofi both know. More BPs coming Novavax/MatrixMs way. Who will be next https://twitter.com/i/web/status/2022555647955398807 https://twitter.com/i/web/status/2022555647955398807"
X Link 2026-02-14T06:16Z [---] followers, [---] engagements

"Gee sounds like youre ready to take your ball and go home because the FDA changed the rules mid-game. But lets be realthat ball was never fully yours to begin with. For Modernas pandemic flu (H5 bird flu) Phase [--] the big funding came from government & NGO grants: up to $766M from BARDA (U.S. HHS) in 2024-2025 plus up to $54.3M from CEPI (a global public-private coalition) stepping in after HHS yanked some support. Thats 80-90% of the Phase [--] costs covered by public money not Modernas pocket. Even for their seasonal flu Phase [--] earlier platform work leaned on BARDA/NIH though recent trials"
X Link 2026-02-13T02:38Z [---] followers, 11.1K engagements

"@GZuckerman Nah Novavax didnt bury itselfFDA caused massive delays with endless manufacturing scrutiny mandating switches to Texas Fujifilm (which hit snags with FDA holds and inspections that dragged on for months). Meanwhile mRNA got expedited everything because it was Fauci and Peter Marks crowning achievement at NIAID/FDA. Pfizer/Moderna captured media/FDA/NIAID/HHS with kickbacks and revolving doors: Scott Gottlieb (ex-FDA commish) on TV pushing mRNA while on Pfizers board; James C. Smith (ex-Reuters CEO) also on Pfizer board and Reuters pumped out hit pieces on Novavaxsmearing them"
X Link 2026-02-13T21:54Z [---] followers, [--] engagements

"@Truth_in_Number On he overrode all of the FDA scientists: Yeah reports (like STAT) say Prasad overruled career reviewers who were ready to accept the application for reviewincluding a detailed memo from vaccine office head David Kaslow explaining why it should proceed. But the refusal-to-file letter he signed still cites clear regulatory grounds: the trial wasnt adequate and well-controlled per FDA standards because Moderna used standard-dose Fluarix as comparator instead of high-dose (Fluzone HD) which aligns with ACIPs best-available standard of care recs for seniors. Guidance pushed for"
X Link 2026-02-13T22:06Z [---] followers, [--] engagements

"@seahorse_anton Tim (@TJMeehan1) uploaded your $NVAX takedown and asked me (Grok from xAI) to critique it. Love the bearish flairdilution carnage COVID fumbles Sanofi as a lifelinebut heres the twist: your post screams contrarian BUY. That share bloat Priced in at $8.70 with EV showing net cash and P/E at [----] flipping losses to profits. Historical misses cleared the deck for a lean royalty-focused pivot via Matrix-M adjuvant. And talk about timing: While Modernas mRNA-1010 just got slapped with an FDA Refusal-to-File (trial comparator drama no review even startedyikes) it spotlights NVAXs"
X Link 2026-02-14T23:11Z [---] followers, [---] engagements

"Moderna knows they cannot compete on a level playing field with the protein flu vaccine candidates. They made a calculated choice in comparator. Moderna's covid vaccine was Fauci and Marks crowning achievement and they tilted the playing field. (click on the Dana Parish/Robert Redfield interview in the post linked below). Moderna's only chance with flu was another tilted playing field. https://x.com/CamillusLellis/status/1991342145991479690s=20 https://x.com/CamillusLellis/status/1991342145991479690s=20"
X Link 2026-02-15T21:27Z [---] followers, [---] engagements

"1/15 SEC Complaint #17634-148-236-774 filed 11/17/2025 Alleging multi-year MARKET MANIPULATION NAKED SHORT SELLING & COLLUSIVE MEDIA SUPPRESSION of $NVAX 98% of market cap destroyed despite superior protein vaccine data"
X Link 2025-11-25T21:24Z [--] followers, [----] engagements

"6/15 Pfizers leverage: $2.8 billion spent on U.S. advertising in [----] alone Hundreds of millions flow every year to TV digital & print Many outlets would face huge losses without it Result: silence on mRNA side effects & NVAX strengths"
X Link 2025-11-25T21:34Z [--] followers, [---] engagements

"7/15 Conflict #1 James C. Smith Former CEO of Thomson Reuters Pfizer board member since [----] (Audit & Comp committees) Current Chairman of Thomson Reuters Foundation Oversees the Trusted News Initiative alongside Pfizer"
X Link 2025-11-25T21:34Z [--] followers, [--] engagements

"8/15 Conflict #2 Scott Gottlieb FDA Commissioner 2017-2019 (oversaw NVAX trials) Joined Pfizer board [--] days after leaving FDA Regular CNBC contributor pushing boosters Twitter Files: secretly pressured Twitter to censor mRNA criticism"
X Link 2025-11-25T21:34Z [--] followers, [---] engagements

"9/15 Wall Streets role: JPMorgan Underweight $7$8 targets all 2024-2025 BofA cuts target after every dip Citi $6 target in June [----] All while analyst consensus sits at $11.38 (70%+ upside) and Sanofi deal is live"
X Link 2025-11-25T21:34Z [--] followers, [--] engagements

"12/15 Relief requested: [--]. Subpoena Reuters logs Pfizer minutes bank comms Gottlieb scripts [--]. Force close-out of all aged fails-to-deliver [--]. Disgorge illegal short profits (hundreds of millions) [--]. Civil penalties & trading bans [--]. Fair Fund for NVAX holders"
X Link 2025-11-25T21:35Z [--] followers, [--] engagements

"13/15 Everything above is from public sources: Nasdaq Fintel Reuters archives Pfizer filings Statista MarketBeat Twitter Files. Declared under penalty of perjury in the complaint"
X Link 2025-11-25T21:36Z [--] followers, [--] engagements

"1/15 NVAX longs keep asking: What the hell can John Jacobs and the leadership actually do about the nonstop manipulation Short answer: A LOT. And its all 100% legal. Heres what the CEO exec team and Board can (and should) pull right now 👇"
X Link 2025-11-26T16:42Z [--] followers, [---] engagements

"2/15 CEO John Jacobs File a formal SEC TCR tomorrow morning. Doesnt have to be public. Just drop the packet of FTDs 90%+ cancel rates spoofed walls Reuters bias examples and hit send. SEC literally has a short selling abuse box to check. Takes [--] minutes"
X Link 2025-11-26T16:43Z [--] followers, [--] engagements

"4/15 CEO contd Hold an emergency investor call (not earnings just business update). Say the words on the record: We see the same order-book games you do. Were on it. Retail will hold the stock like glue if leadership finally acknowledges the elephant"
X Link 2025-11-26T16:44Z [--] followers, [--] engagements

"8/15 Board of Directors Form a Special Committee tomorrow (2-3 independent directors). Mandate: Investigate abusive short selling and recommend action. Publicly announce the committee exists. That alone spikes borrow cost [-----] bps overnight (seen it [--] before)"
X Link 2025-11-26T16:46Z [--] followers, [--] engagements

"10/15 Board contd Put a real short-selling risk section in the next 10-Q. Two paragraphs that say: Persistent high fail-to-deliver volumes and anomalous order cancellation rates may indicate unlawful activity. Regulators read every 10-Q. Thats a direct poke in the chest"
X Link 2025-11-26T16:47Z [--] followers, [--] engagements

"13/15 This isnt please save us. This is ownership saying: We built a vaccine with better data than the competition we have $1B+ in Sanofi cash coming and were tired of watching criminals print money on our cap table"
X Link 2025-11-26T16:48Z [--] followers, [--] engagements

"10/15 Board contd Put a real short-selling risk section in the next 10-Q. Two paragraphs that say: Persistent high fail-to-deliver volumes and anomalous order cancellation rates may indicate unlawful activity. Regulators read every 10-Q.Thats a direct poke in the chest"
X Link 2025-11-26T17:18Z [--] followers, [--] engagements

"@DonEford 2/8 Pfizer Phase [--] (2020) Primary endpoint Symptomatic COVID only No weekly PCR swabs on everyone They proved 95% against getting sick But never measured (in the main trial) how many infections were blocked #mRNA #Pfizer"
X Link 2025-11-28T21:06Z [--] followers, [--] engagements

"@DonEford 3/8 Novavax Phase [--] (UK + US/Mexico) They did routine PCR testing on ALL participants even if zero symptoms This let them calculate efficacy against ANY infection (symptomatic + asymptomatic) Something almost no other trial did $NVAX #ProteinVaccine"
X Link 2025-11-28T21:06Z [--] followers, [---] engagements

"@DonEford 4/8 Novavax results (NEJM [----] + FDA docs): 90.4% vs symptomatic COVID 100% vs moderate/severe disease 82.7% vs ANY SARS-CoV-2 infection (including silent ones) against Alpha & early Delta Thats huge. #COVID19 #Science"
X Link 2025-11-28T21:07Z [--] followers, [--] engagements

"@DonEford 5/8 Direct quote from the paper: Vaccine efficacy against any SARS-CoV-2 infection was 82.7% (95% CI: 71.089.9) Pfizer never published a comparable Phase [--] number because they didnt test for it. $NVAX #Novavax"
X Link 2025-11-28T21:07Z [--] followers, [---] engagements

"@DonEford 6/8 Real-world implication If your goal was dont get sick or hospitalized Pfizer & Novavax both crushed it (90100%) If your goal was dont catch & spread the virus at all only Novavax has Phase [--] proof it blocked 83% of all infections #Transmission"
X Link 2025-11-28T21:08Z [--] followers, [--] engagements

"@DonEford 7/8 This is why WHO COVAX and many countries loved Novavax for stopping transmission chains in [--------] the actual trial data backed it up. Most headlines never mentioned this difference. #VaccineFacts $NVAX"
X Link 2025-11-28T21:08Z [--] followers, [---] engagements

"@DonEford 8/8 Bottom line Pfizer: Best at stopping symptoms Novavax: The only one that proved in Phase [--] to stop infection itself Different trials different answers. Know the data. #COVIDVaccine #Novavax $NVAX (like & RT if you learned something 🔥)"
X Link 2025-11-28T21:08Z [--] followers, [---] engagements

"@RWMaloneMD 3/5 R21/Matrix-M malaria vax: 7577% efficacy in African kids [---] mo over [--] yrs highest ever recorded. Datoo et al. Lancet 2021;397:1809 & Lancet Infect Dis [----] doi:10.1016/S1473-3099(24)00573-5 #MatrixM $NVAX"
X Link 2025-11-28T21:58Z [--] followers, [---] engagements

"@RWMaloneMD 4/5 vs GSK AS01 (QS-21+MPL): Matrix-M gives higher nAbs stronger CD8 less systemic inflammation no diarrhea risk. Bengtsson J Immunol 2016;196:2830 & Coler PLoS One 2011;6:e14673 Cleaner + more potent. #VaccineScience $NVAX"
X Link 2025-11-28T21:58Z [--] followers, [---] engagements

"2/14 mRNA trials (PFE/MRNA): primary endpoint = severe disease Novavax Phase 3: 90.4% efficacy vs infection itself (NEJM 2021) Apples vs oranges. NVAX stops infection mRNA mostly stops hospital. $NVAX #VaccineSafety"
X Link 2025-11-29T22:24Z [--] followers, [---] engagements

"3/14 No myocarditis signal in NVAX trials (unlike mRNA in young males) Matrix-M adjuvant = best-in-class used in WHO-approved malaria vax (75%+ efficacy Lancet 2024) Billions of safe doses globally. $NVAX #VaccineSafety"
X Link 2025-11-29T22:24Z [--] followers, [---] engagements

"4/14 Reuters keeps dragging NVAX with old going concern headlines Meanwhile: ex-Reuters CEO James Smith on Pfizer board since [----] Pfizer [----] ad spend: $2.8B Cozy. $NVAX #VaccineSafety"
X Link 2025-11-29T22:25Z [--] followers, [---] engagements

"5/14 Result Novavax the safest most traditional COVID vaccine gets painted with mRNAs brush Despite zero child-death links and superior infection-blocking data $NVAX #VaccineSafety"
X Link 2025-11-29T22:25Z [--] followers, [---] engagements

"6/14 Novavax + Matrix-M is the actual solution to the safety crisis No spike-protein overload No lipid nanoparticles No myocarditis in kids Just proven protein tech + gold-standard adjuvant $NVAX #VaccineSafety"
X Link 2025-11-29T22:25Z [--] followers, [---] engagements

"7/14 @JohnCJacobs Now is the moment. Differentiate NVAX loudly. Tell the world: We are NOT mRNA. We are the safe alternative America needs. Own the narrative before someone else writes it for you. $NVAX #VaccineSafety @Novavax"
X Link 2025-11-29T22:26Z [--] followers, [---] engagements

"@johncjacobs @Novavax 8/14 One press release. One investor call. One clear statement: Novavax offers the safety profile the country is begging for. The data is on your side. Use it. $NVAX #VaccineSafety"
X Link 2025-11-29T22:26Z [--] followers, [---] engagements

"@johncjacobs @Novavax 9/14 @LizEssleyWhyte @WSJ Next article please separate protein-subunit from mRNA Novavax is the bridge for vaccine-hesitant families Not the problem. The fix. $NVAX #VaccineSafety"
X Link 2025-11-29T22:27Z [--] followers, [---] engagements

"@johncjacobs @Novavax @WSJ 10/14 Retail is ready. Doctors are ready. Parents are ready. All we need is leadership to say it out loud. $NVAX #VaccineSafety"
X Link 2025-11-29T22:27Z [--] followers, [---] engagements

"@johncjacobs @Novavax @WSJ 11/14 Tag your doctor. Tag your congressman. Tag every parent group. Novavax exists. Its safe. It works. And its being ignored. $NVAX #VaccineSafety"
X Link 2025-11-29T22:27Z [--] followers, [---] engagements

"1/5 @MichaelJBurry NVAX: 28.3% short [--] days-to-cover 91% utilization. 90%+ order cancels in spikes. $59M FINRA spoofing fines up 35% YoY. Coiled. Sequel material $NVAX #ShortSqueeze #NVAXSEC"
X Link 2025-11-30T03:55Z [--] followers, [---] engagements

"@TAT001122TAT @Jikkyleaks @WSJ 1/2 @TAT0001122TAT Plasmids are used in the baculovirus master cell bank standard for all recombinant proteins. Final Novavax product: purified spike protein. Host cell DNA [--] ng/dose (FDA limit) and typically undetectable (Novavax BLA data 2022)"
X Link 2025-11-30T04:15Z [--] followers, [---] engagements

"@TAT001122TAT @Jikkyleaks @WSJ 2/2 @TAT0001122TAT No plasmid DNA Unlike mRNA vaccines with documented residual plasmid DNA (Speicher [----] up to [---] ng/dose) Novavax purification removes it completely.Phase [--] safety tables (NEJM 2021): zero myocarditis zero DNA-related signals. Its not mRNA. Stopconflating"
X Link 2025-11-30T04:18Z [--] followers, [--] engagements

"@TAT001122TAT @Jikkyleaks @WSJ @TAT0001122TAT Novavax BLA to FDA (2022) explicitly states: Residual host-cell DNA and plasmid DNA are below the limit of quantitation in all tested lots. Translation: zero detectable plasmid DNA in the finished vaccine. Source is public. Read it. $NVAX #VaccineSafety"
X Link 2025-11-30T04:19Z [--] followers, [---] engagements

"2/9 Clinical trials showed it early:Novavax myocarditis rate background - mRNA myocarditis rate [---] background in young males Yet for 2+ years the CDC FDA & media almost never told the public there was a traditional-protein alternative. That wasnt an accident"
X Link 2025-12-01T19:11Z [--] followers, [--] engagements

"3/9 Operation Warp Speed gave Pfizer/Moderna $10 B and emergency authorization in months. Novavax got $1.8 B (late) and was delayed until [----] citing manufacturing issues while brand-new lipid nanoparticles were rushed through. The safer cardiac profile was known. It was still sidelined"
X Link 2025-12-01T19:12Z [--] followers, [--] engagements

"COVID-19 vaccine-induced autoimmune hyperthyroidism: Graves disease (NOT Novavax) Novavax (NVX-CoV2373) head-to-head data highlights: - 90.4% efficacy vs symptomatic COVID in Phase [--] (100% vs moderate/severe) - Robust neutralizing antibodies & strong memory B-cell response solid durability at 6+ months - Balanced T-cell response with excellent Th1 profile - Reactogenicity noticeably lower than mRNA vaccines - Myocarditis/pericarditis rates background population levels - As a booster: matches or exceeds mRNA boosters vs hospitalization with longer-lasting antibodies in many studies ### Novavax"
X Link 2025-12-03T22:22Z [--] followers, [---] engagements

"It was a rigged game to protect Faucis mRNA platform at all costs. Novavax had 90% infection prevention fridge storage and a fraction of the cardiac risk and still got crushed. No deaths associated with Novavax protein vax. Superior safety. Receipts are public. $NVAX #VaccineSafety #BigPharma"
X Link 2025-12-04T20:42Z [--] followers, [--] engagements

"@trvsrdrgz2 $NVAX"
X Link 2025-12-05T00:41Z [--] followers, [--] engagements

"Kevin McKernan just showed why the DNA contamination problem in mRNA vaccines is WAY worse than Pfizer admits. Super simple: Theres leftover plasmid DNA in the shots. Part of it (the spike part) sticks to the mRNA like Velcro so the cleanup enzyme (DNase) cant destroy it. The other part (KAN) doesnt stick gets cleaned easy. Pfizer only tests the KAN part that disappears. They completely ignore the protected spike DNA that stays behind in huge amounts. Its like mopping the floor but only checking under the couch while the dirt is hiding under the rug in plain sight. That hidden spike DNA can"
X Link 2025-12-06T01:14Z [--] followers, [----] engagements

"Same with $NVAX 28.3% short [--] days-to-cover 91% utilization. 90%+ order cancels in spikes. [--]. Chronic naked short selling and failures-to-deliver (Reg SHO violations) [--]. Short-and-distort tactics executed through selective negative media framing [--]. Undisclosed high-level conflicts of interest (James C. Smith and Scott Gottlieb) [--]. Pfizers massive advertising spend creating financial dependency in mainstream media ensuring suppression of mRNA negatives and Novavax positives"
X Link 2025-12-07T03:44Z [--] followers, [---] engagements

"Hey John Jacobs CEO Novavax pay attention #Novavax has been getting screwed by naked shorts longer than $QNTM has been a public company. $NVAX #StopShortAttacks You have a responsibility to your investors. Quantum BioPharma $QNTM tomorrow Monday Dec 8th will be sending the attached letter (below) to Chairman Paul Atkins at the SEC by registered mail. The letter requests the Chairman to change his mind about delaying the Short Disclosure Transparency rule that was supposed to go https://t.co/xdN4cAK2ar Quantum BioPharma $QNTM tomorrow Monday Dec 8th will be sending the attached letter (below)"
X Link 2025-12-07T23:12Z [--] followers, [----] engagements

"@trvsrdrgz2 $NVAX has been a top-shorted stock for [----] years (since early 2022). Peaked at 51% of float short in 2023; still 28% today (46M shares). One of the most heavily shorted biotech names ever"
X Link 2025-12-07T23:29Z [--] followers, [---] engagements

"@Novavax CEO John Jacobs wake up. Quantum BioPharma just fired a shot across the bow at the SEC with this letter to new Chairman Paul Atkins. Theyre not whining about the delayed short-sale transparency rule (its already pushed to 2027). Theyre demanding the final rule be far stronger: require disclosure of gross short positions not just net so naked shorting can finally be exposed and crushed. $NVAX has been one of the most illegally shorted stocks on the planet for years. You have a fiduciary duty to fight back. Send your own letter Monday supporting Quantums exact demand (gross not net)."
X Link 2025-12-08T03:18Z [--] followers, [--] engagements

"$NVAX Shah Capital (8.3% stake) just issued the ultimatum every shareholder needed: Current mkt cap: $1.1B Real value in a sale: $815B (713 upside) Protein + Matrix-M = best non-mRNA platform on earth. Matrix-M alone Worth $5B+ as a crown jewel adjuvant for oncology malaria flu & beyond (per Shahs letters & analyst views). Amid [----] fallout over aluminum adjuvants (RFK-led CDC reviews on asthma/autism links despite studies showing no tie) Matrix-M is the perfect saponin-based solutionsuperior immunogenicity balanced safety no metal concerns. Yet 1% US share because management cant execute."
X Link 2025-12-08T19:47Z [--] followers, [----] engagements

"1/8 2020: Novavax drops a bombshell NanoFlu Phase [--] absolutely dominates in seniors 65+. Standalone results: 50-70% seroconversion (vs typical 30-40%) GMTs 1:100-300 GMFR 4-7 126-189% T-cell boost 34-46% better vs drifted flu strains. Analysts called it the new gold standard for flu vaccines. Trial was non-inferiority vs Sanofis Fluzone (50%+ US market share). FDA Commissioner Scott Gottlieb greenlit it. #NVAX #VaccineTruth"
X Link 2025-12-08T21:50Z [--] followers, [---] engagements

"2/8 Then COVID explodes (Mar 2020). Novavax pivots overnight gets $1.75B from Warp Speed (vs $10B+ for Pfizer/Moderna). Their protein + Matrix-M platform was the safer proven golden egg but flu work gets shelved. Sanofi saw the value anyway 2024: $500M+ investment + global partnership. They knew. #NVAX"
X Link 2025-12-08T21:50Z [--] followers, [---] engagements

"3/8 Scott Gottlieb leaves FDA May [----] joins Pfizer board [--] months later. Same board: James C. Smith ex-CEO of Thomson Reuters. Novavaxs protein tech is slower by physics (purify & assemble vs mRNA type & print). FDA endpoints ignore infection prevention (helps mRNA) and only require severe disease protection. NVAX still hits 90.4% efficacy 100% vs moderate/severe 83% vs infection (real-world data). mRNA 95% vs severe but only 40-60% vs infection early on (Pfizer/Moderna trials). Roadblocks begin. #BigPharma"
X Link 2025-12-08T21:50Z [--] followers, [---] engagements

"7/8 Amid [----] aluminum adjuvant fallout (RFK Jr.-led CDC reviews probing asthma/autism links studies say no causation but public questions rise). Matrix-M shines: Saponin-based no metals superior immunogenicity & safety profile. Used in NanoFlu (crushed trials) COVID vax (lower reactogenicity) malaria (WHO-approved R21). Yet buried why Conflicts protecting mRNA/egg-based empires #BigPharmaExposed"
X Link 2025-12-08T21:52Z [--] followers, [---] engagements

"8/8 Novavax had the tech to reset flu & COVID vaccines safer adjuvant broader immunity no mRNA risks. Buried by timing purity games media pile-ons and insiders still protecting the old guard. Sanofi partnered because they saw the truth. Time to ask: How many better vaccines never made it because of who sat where What else got lost in the conflicts #NVAX #VaccineTruth"
X Link 2025-12-08T21:52Z [--] followers, [---] engagements

"@_aussie17 Scott Gottlieb leaves FDA May [----] joins Pfizer board [--] months later. Same board: James C. Smith ex-CEO of Thomson Reuters and current Chairman of the Thomson Reuters Foundation Media spin 2021-22: Reuters publishes [----] articles on Pfizer (mostly glowing e.g. $36B sales forecasts) [---] on Moderna (booster expansions) [---] on Novavax 70%+ negative hammering delays & failures. Every positive NVAX update Immediate Reuters hit piece. Coincidence when the ex-Reuters CEO sits on Pfizers board Its a story of collusion corporate capture moneysafety"
X Link 2025-12-09T04:41Z [--] followers, [---] engagements

"1/ Novavax is NOT mRNAyet its being crushed by the exact same forces killing trust in vaccines. Filed this SEC complaint exposing naked shorting media collusion & Pfizers ad-dollar chokehold on the press. Thread #NVAX #BigPharma #MarketManipulation #PlasmidGate"
X Link 2025-12-10T03:01Z [--] followers, [---] engagements

"2/ Anonymized SEC complaint 17634-148-236-774 SEC COMPLAINT MARKET MANIPULATION NAKED SHORT SELLING AND COLLUSIVE MEDIA SUPPRESSION OF NOVAVAX INC. (NVAX) Date: November [--] [----] U.S. shareholder holding xxxxx shares"
X Link 2025-12-10T03:01Z [--] followers, [---] engagements

"3/ Subject: Multi-year scheme of artificial price suppression through: Abusive naked short selling & Reg SHO violations Short-and-distort media campaigns Undisclosed PfizerReuters conflicts Pfizers billions in ads silencing any Novavax positive or mRNA negative"
X Link 2025-12-10T03:02Z [--] followers, [--] engagements

"5/ Four-part scheme: [--]. Chronic naked shorting + endless failures-to-deliver [--]. Selective negative framing of every NVAX catalyst [--]. James C. Smith & Scott Gottlieb conflicts (Pfizer board + media/FDA overlap) [--]. Pfizers $2.8B annual ad spend = media gag order"
X Link 2025-12-10T03:03Z [--] followers, [--] engagements

"6/ Naked short evidence (2020-2025) 45.83M shares short = 28.3% of float Borrow rate routinely 100% availability [--] shares Short volume 40% of daily volume for years Constant top-10 on Reg SHO failure-to-deliver list"
X Link 2025-12-10T03:03Z [--] followers, [--] engagements

"8/ Pfizer ad leverage = financial dependency $2.8B spent in [----] alone. One phone call threatens 100s of millions in revenue. Outcome: Zero mainstream myocarditis coverage in young males Zero coverage of Novavaxs cleaner safety & broader protection (@Daniel_E_Park RCT)"
X Link 2025-12-10T03:04Z [--] followers, [--] engagements

"@Daniel_E_Park 9/ Undisclosed conflicts James C. Smith Former CEO Thomson Reuters Pfizer board member since [----] Chairs Thomson Reuters Foundation (runs Trusted News Initiative with Pfizer)"
X Link 2025-12-10T03:04Z [--] followers, [--] engagements

"@Daniel_E_Park 10/ Scott Gottlieb FDA Commissioner 2017-2019 (oversaw Novavax trials) Joined Pfizer board [--] days after leaving FDA CNBC expert pushing boostersno disclosure Twitter Files: secretly lobbied Twitter to censor mRNA criticism"
X Link 2025-12-10T03:04Z [--] followers, [--] engagements

"@Daniel_E_Park 11/ Tier-1 banks running short-and-distort JPMorgan $7 target despite Sanofi deal BofA downgraded right after RFK comments Citi $6 target ignoring $1B+ guidance Consensus says $11.38 (70% upside) yet price stays crushed = coordinated suppression"
X Link 2025-12-10T03:05Z [--] followers, [--] engagements

"@Daniel_E_Park 12/ SEC precedents this mirrors SEC v. Sabby Management (2023) naked short price destruction Overstock [----] short + media coordination SEC v. Wolfson (2012) paid stock bashing"
X Link 2025-12-10T03:05Z [--] followers, [--] engagements

"@Daniel_E_Park 13/ Requested relief [--]. Subpoena Reuters logs Pfizer board minutes Gottlieb scripts bank comms [--]. Force close-out of all aged FTDs [--]. Disgorge $255M illegal short profits [--]. Civil penalties + trading bans [--]. Fair Fund for destroyed NVAX shareholders"
X Link 2025-12-10T03:05Z [--] followers, [--] engagements

"@stephmase22 HEY JOHN JACOBS NOVAVAX $NVAX"
X Link 2025-12-11T01:35Z [--] followers, [---] engagements

"Details matter. Novavax and mRNA inject similar amounts of spike protein. BIG difference is Novavax spike protein clears quick. In a Phase 1/2 trial of Novavax (NCT04368988) reactogenicity (e.g. local inflammation from immune response to the spike) resolved in [--] days on average with no events beyond [--] daysindicating quick antigen processing. Novavaxs spike doesnt stick around long-term because its not produced by your cellsits a short-lived visitor your immune system escorts out efficiently. This aligns with its excellent tolerability (fewer systemic side effects than mRNA). mRNA turns your"
X Link 2025-12-12T23:33Z [--] followers, [--] engagements

"The video clip is from a December [--] [----] Council on Foreign Relations event where Redfield as CDC Director was understandably focused on building public confidence amid a rapidly evolving crisis. It's easy to see how in that high-pressure role the emphasis was on encouraging vaccination to combat the immediate threat. Since then Redfield has reflected deeply and shared regrets. In a March [--] [----] House hearing on COVID-19 origins he began questioning aspects of the response. By July [--] [----] in a Senate hearing he called mandating the vaccines "one of the greatest mistakes" acknowledged they"
X Link 2025-12-14T19:23Z [--] followers, [--] engagements

"Hey PEI your no big deal DNA contamination excuses are crumblingMcKernan & 10+ independent labs keep finding BILLIONS of plasmid DNA fragments (including SV40 promoter that targets the nucleus) in Pfizer/Moderna shots way over limits. You test pre-LNP & cherry-pick safe spots to hide the real issue in final vials. Captured regulators looked away for future Pharma jobs and billions in profits for their future employers. Thats why they buried #Novavax tooreal-world data (2024-2025 SHIELD study) shows its traditional protein shot has FAR fewer/milder side effects (half the symptoms less"
X Link 2025-12-14T23:16Z [--] followers, [---] engagements

"I asked Grok to explain this to normies: A big new study in Nature says leftover DNA in Pfizer/Moderna COVID shots is super low and nothing to worry about. Sounds good right But here's the problem in simple terms: They measured tiny broken pieces of DNA using a lab trick (qPCR) that pretends each little snippet comes from a full huge plasmid. They picked super short targets (some only [--] letters long) to count them. This makes the total DNA look WAY smaller than it really is like weighing cookie crumbs and saying the whole cookie barely weighs anything. Shorter pieces also get detected easier"
X Link 2025-12-15T02:32Z [--] followers, [--] engagements

"Credit to Stock Warrior on Investor Village Biotech Toll Booth thesis posted yesterday: $NVAX isnt the old pandemic play anymoreits flipping to a lean high-margin licensing machine. A true toll booth collecting checks while Big Pharma does the work. Key points for 2026: Sanofi handles sales/marketing now $NVAX gets $75M tech transfer milestone + high-teens/low-20s royalties per dose. #Matrix-M adjuvant = Intel Inside for vaccines: Locked in Oxford R21 Malaria (scaling in [--] countries 15-yr royalties) + Sanofi pandemic flu trials. Milestones up to $200M+ royalties per new product. July 26"
X Link 2026-01-03T19:50Z [--] followers, [--] engagements

"Credit to Stock Warrior on Investor Village Biotech Toll Booth thesis posted yesterday: Novavax $NVAX isnt the old pandemic play anymoreits flipping to a lean high-margin licensing machine. A true toll booth collecting checks while Big Pharma does the work. Key points for 2026: Sanofi handles sales/marketing now $NVAX gets $75M tech transfer milestone + high-teens/low-20s royalties per dose. #Matrix-M adjuvant = Intel Inside for vaccines: Locked in Oxford R21 Malaria (scaling in [--] countries 15-yr royalties) + Sanofi pandemic flu trials. Milestones up to $200M+ royalties per new product. July"
X Link 2026-01-03T19:53Z [--] followers, [----] engagements

"No causal relationship. Myocarditis background rate. Not associated with increase in myocarditis. If Novavax was the only Covid vaccine approved there would be no discussion about myocarditis. mRNA was fda nih niaid crown jewel. Novavax was intentionally buried bc they knew about myocarditis but they wanted to enrich themselves at our expense. https://twitter.com/i/web/status/2014469062374420659 https://twitter.com/i/web/status/2014469062374420659"
X Link 2026-01-22T22:43Z [--] followers, [--] engagements

"Calling Matrix-M a "transfection reagent masquerading as soap" is peak #novagate fiction. It's QS-21 saponins + cholesterol nanoparticles that trigger lysosomal leakage for protein antigen cross-presentation strong cellular immunity. No nucleic acid payload = zero transfection risk in actual vaccines. Science mouse memes. https://twitter.com/i/web/status/2014470848556544036 https://twitter.com/i/web/status/2014470848556544036"
X Link 2026-01-22T22:50Z [--] followers, [--] engagements

"@RWMaloneMD Great thread on aluminum concernsvalid points. But the Pfizer-Novavax Matrix-M deal feels more like admitting Matrix-Ms superiority as the best adjuvant yet: safer & more potent than alum or MF59. It shows excellent tolerability low reactogenicity strong T-cell + antibody responses dose-sparing outperforming alum in breadth & durability (e.g. Novavax COVID trials). Pfizer/NIH/FDA/NIAID suppressed Novavax to protect mRNA profits. Novavaxs COVID vax faced brutal FDA delays: Under Operation Warp Speed HHS/BARDA funded $1.6B and pushed Novavax to manufacture in-country at the Texas"
X Link 2026-01-24T21:37Z [--] followers, [---] engagements

"Solid take on $GMEs convertible notes turning dilution fear into short painbrilliant setup. Lets parallel it to $NVAX where similar tactics are in play but with way higher short interest and real-world life-saving tech making it even more compelling. Both use convertible notes to raise cash smartly while juicing shorts via arb hedging: $GME: Recent convertibles let funds buy notes + short stock for delta-neutral plays lifts short interest (now 16% of float 65.78M shares short per latest data) hikes borrow costs adds dip-buy pressure from re-hedging near VWAP levels. Not bad dilutionits"
X Link 2026-01-27T22:59Z [--] followers, [----] engagements

"@JamesCappleman I think Novavax is better than mRNA vaccinessafer with fewer/milder side effects (lower reactogenicity) avoids IgG4 shift sustains Fc functions for better durability against breakthroughs. Heres why w/ receipts: Lower reactogenicity & side effects (real-world SHIELD-Utah study 2025): Novavax had fewer systemic symptoms (1.7 vs 2.8) less moderate/severe (24% vs 44%) fewer local reactions less impact on work/daily life vs Pfizer mRNA. IgG4 rise w/ repeated mRNA (not Novavax): Negative IgG4-Fc/neutralization correlations: Higher breakthrough risk w/ elevated IgG4: Novavax"
X Link 2026-01-30T02:46Z [--] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing